Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Operating Expenses (2017 - 2025)

Aclaris Therapeutics has reported Operating Expenses over the past 9 years, most recently at $24.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $24.0 million for Q4 2025, down 77.93% from a year ago — trailing twelve months through Dec 2025 was $84.2 million (down 47.59% YoY), and the annual figure for FY2025 was $84.2 million, down 47.59%.
  • Operating Expenses for Q4 2025 was $24.0 million at Aclaris Therapeutics, up from $20.4 million in the prior quarter.
  • Over the last five years, Operating Expenses for ACRS hit a ceiling of $108.9 million in Q4 2024 and a floor of $14.8 million in Q3 2024.
  • Median Operating Expenses over the past 5 years was $22.2 million (2021), compared with a mean of $29.5 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 403.71% in 2024 and later tumbled 77.93% in 2025.
  • Aclaris Therapeutics' Operating Expenses stood at $24.4 million in 2021, then surged by 50.99% to $36.8 million in 2022, then tumbled by 41.31% to $21.6 million in 2023, then skyrocketed by 403.71% to $108.9 million in 2024, then tumbled by 77.93% to $24.0 million in 2025.
  • The last three reported values for Operating Expenses were $24.0 million (Q4 2025), $20.4 million (Q3 2025), and $20.2 million (Q2 2025) per Business Quant data.